Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2010Journal of Clinical OncologyOpen Access

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

APAntonio PalumboSemmelweis UniversitySGSara GalimbertiUniversity of SienaDRDavide RossiOspedale di Santo Spirito

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Palumbo et al. (2010) studied this question.

synapsesocial.com/papers/6a10eecbb1f64a72d764621chttps://doi.org/10.1200/jco.2010.29.8216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1International Staging System for Multiple Myeloma2005 · 2,959 citations
  2. 2Maintenance therapy with thalidomide improves survival in patients with multiple myeloma2006 · 673 citations
  3. 3First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)2008 · 66 citations
  4. 4Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study2008 · 52 citations
  5. 5A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.2009 · 48 citations